Equity · Healthcare
BDTX
NASDAQBlack Diamond Therapeutics (BDTX)
The line runs 2.16 USD on 24 August through 1.33 USD on 20 November, on a scale from 1.0 to 2.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 76.4M USD
- Revenue, year to Dec 2025
- 70.0M USD
- EPS, diluted, year to Dec 2025
- 0.39 USD
- 52-week range
- 1.33 USD – 4.48 USD
- Avg volume
- 52.8K
as of Nov 20, 2026
Have Black Diamond Therapeutics (BDTX) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, no Black Diamond Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest Form 4 filing 18 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 Sep 2026 | Raman PrakashDirector | Award | 6,801 | 13K USD |
| 18 Sep 2026 | Behbahani AliDirector | Award | 7,707 | 15K USD |
Which funds hold Black Diamond Therapeutics (BDTX)?
6 of the 45 institutional funds we track reported a Black Diamond Therapeutics position for the quarter ended 30 Sep 2026 — a combined 7.8M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 1,652,100 | 3.1M USD | −15.8% |
| Marshall Wace | Added | 1,176,357 | 2.2M USD | +31.2% |
| AQR Capital Management | New position | 889,633 | 1.7M USD | |
| D. E. Shaw & Co. | Added | 278,469 | 525K USD | +77.0% |
| Balyasny Asset Management | Trimmed | 87,313 | 165K USD | −83.9% |
| Two Sigma Investments | Held (±25%) | 40,604 | 77K USD | −3.3% |
What has been filed or recorded for Black Diamond Therapeutics (BDTX)?
The filings we hold for Black Diamond Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 12,177 shares | 23K USD notional · 0.021% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,385 shares | 9K USD notional · 0.008% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,795 shares | 5K USD notional · 0.005% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.17 USD | |
| 30 Sep 2026 | Financials | Total assets | 115.6M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 88.1M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.17 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.16 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.39 USD | |
| 31 Dec 2025 | Financials | Revenue | 70.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 22.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.39 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.15 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.19 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.98 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.27 USD |
What do people ask about Black Diamond Therapeutics (BDTX)?
What did Black Diamond Therapeutics shares close at?1.33
Black Diamond Therapeutics closed at 1.33 USD on 20 Nov 2026, down 4.32% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Black Diamond Therapeutics’ market cap?76.4M
Black Diamond Therapeutics is worth 76.4M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Black Diamond Therapeutics’ revenue?70.0M
Black Diamond Therapeutics reported revenue of 70.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Black Diamond Therapeutics insiders bought or sold shares recently?2 filings
In the 90 days to 22 Nov 2026, no Black Diamond Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Black Diamond Therapeutics?6 of 45
6 of the 45 funds we track reported a Black Diamond Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Marshall Wace and AQR Capital Management. See Funds
When did Black Diamond Therapeutics last report earnings?−0.17
Black Diamond Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.17 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words